

No stain
Secondary Ab-APC only
Primary Ab + Secondary Ab-APC
YS5FL
Isotype Control
LnCap-C4-2B
LnCap-C4
DU145
Count
APC-A

FIG. 1



No stain
Secondary Ab-APC only
Primary Ab + Secondary Ab-APC
YS5FL
Isotype Control
PC3-luc
Hs27
BPH1
Count
APC-A
Sample1
Sample2
Sample3
Sample4

FIG. 1 (Cont.)



No stain
Secondary Ab-APC only
Primary Ab + Secondary Ab
YS5FL
Isotype Control
RPMI8226
MM.1S
MM.1R
INA6
Count
APC-A

FIG. 2





FIG. 3



2095-CON-18001 DS					
mAb	Drug 2	Drug 4	Drug 6	Drug 8	DAR
4.365%	28.365%	43.764%	16.220%	3.005%	3.689

FIG. 4





FIG. 5A



Nadir of -71% drop in PSA

FIG. 5B



Weeks on Treatment
Subject ID
004-04-009
004-05-017
001-06-018
004-05-014
004-05-013
001-08-026
004-08-025
001-08-027
004-05-016
001-03-005
001-08-024
001-09-028
002-05-015
004-06-019
005-09-029
001-03-007
001-02-002
003-04-008
004-05-011
004-09-030
001-01-001
001-10-033
004-07-021
001-03-006
003-07-022
001-02-003
001-02-004
001-04-010
001-05-012
004-06-020
0
10
20
30
40
50
60
70
80
90
Weeks
BestResponse
PR, > 50% PSA↓
> 50% PSA↓
Other
Event
EOS
EOT
PD

FIG. 6




FIG. 7A




FIG. 7B




FIG. 7C



Weeks on Treatment
Subject ID
001-06-012
003-05-009
005-06-101
006-05-008
001-06-102
003-06-014
005-06-104
006-06-106
006-06-103
001-04-004
001-03-003
007-04-005
002-05-007
001-06-109
006-06-010
007-04-006
001-06-107
003-06-015
006-06-011
001-02-002
001-06-108
001-06-105
002-06-110
001-01-001
001-06-013
0
10
20
30
Weeks
BestResponse
Partial Response
Minimal Response
Other
Event
EOS
EOT
PD

FIG. 8